alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Charlie VINING and Velma Vining, wife of Charlie Vining, Appellants, v. AVIS RENT-A-CAR SYSTEMS, INC., Appellee.

No. 75-756.

District Court of Appeal of Florida, Third District.

Feb. 28, 1978.

Papy, Levy, Carruthers & Poole and Sheridan K. Weinstein, Coral Gables, for appellants.

*227Richard M. Gale, Robert L. Dube, Miami, for appellee.

Before PEARSON, BARKDULL and NATHAN, JJ.

ORDER ON MANDATE

PER CURIAM.

WHEREAS, the judgment of this court was entered on April 20,1976 affirming the order of the circuit court of Dade County, Florida, in the above styled cause; and

WHEREAS, on review of this court’s judgment, by certiorari, the Supreme Court of Florida by its opinion and judgment filed November 10, 1977 (354 So.2d 54) and mandate now lodged in this court, quashed this court’s judgment;

NOW, THEREFORE, It is Ordered that the judgment of this court filed April 20, 1976 is vacated and the said opinion and judgment of the Supreme Court of Florida is herewith made the opinion and judgment of this court, the order of the trial court appealed herein is reversed and the cause is remanded for further proceedings consistent with the opinion and judgment of the Supreme Court of Florida. Costs allowed shall be taxed in the trial court (Rule 3.16(b), Florida Appellate Rules).
[Federal Register Volume 62, Number 167 (Thursday, August 28, 1997)]
[Notices]
[Page 45670]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-22978]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


System Suitability (Validation) of Chromatographic Analysis/Out-
of-Specification Results; Notice of Public Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The Food and Drug Administration (FDA) is announcing that it will 
hold a series of two public meetings that will be offered in two 
locations. The topics to be discussed are validating chromatographic 
systems and evaluating out-of-specification test results.
    Date and Time: The public meetings will be held on September 12, 
1997, 8 a.m. to 12 m. and 1 p.m. to 4 p.m.; and September 24, 1997, 2 
p.m. to 5:30 p.m. (both meetings).
    Location: On September 12, 1997, the meetings will be held at the 
Independence Seaport Museum Penn's Landing, 211 South Columbus Blvd., 
and Walnut St., Philadelphia, PA, 215-413-8622, FAX 215-925-6713. On 
September 24, 1997, the meetings will be held at the Hyatt Regency 
Bethesda, One Bethesda Metro Center, Bethesda, MD, 301-657-1234, FAX 
301-657-6453.
    Contact: Richard A. Baldwin, Division of Field Science (HFC-141), 
Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 
301-443-6388, FAX 301-443-5153.
    Registration: Registration for the September 24, 1997, meetings is 
required through the Parenteral Drug Association. For more information 
on how to register, contact the Parenteral Drug Association at 301-986-
0293, or e-mail <a href="/cdn-cgi/l/email-protection#b4dddad2dbf4c4d0d59adbc6d3"><span class="__cf_email__" data-cfemail="0b62656d644b7b6f6a2564796c">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: On September 12, 1997, FDA's Office of 
Regulatory Affairs and the Office of External Affairs are cosponsoring 
two meetings entitled ``System Suitability (Validation) for 
Chromatographic Analysis'' and ``Out-of Specification Results.'' On 
September 24, 1997, FDA, in cooperation with the Parenteral Drug 
Association, will offer the same meetings in Bethesda MD. The goal of 
these meetings is to provide consistent practices and procedures 
between FDA and the pharmaceutical industry.
    Requests for handouts are available from the Division of Field 
Science. Submit requests to Denise Jones, Division of Field Science 
(HFC-141), Food and Drug Administration, 5600 Fishers Lane, Rockville, 
MD 20857.
    If you need special accommodations due to a disability, please 
notify the contact person at least 7 days in advance.

    Dated: August 22, 1997.
William B. Schultz,
Deputy Commissioner for Policy.
[FR Doc. 97-22978 Filed 8-25-97; 4:44 pm]
BILLING CODE 4160-01-F


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
**CERTIFICATION      OF PERIODIC REPORT**

| (1) | the                  Quarterly Report on Form 10-Q of the Company for the quarterly                  period                  ended June 30, 2007 (the “Report”) fully complies with the requirements of                  Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15                  U.S.C.                  78m or 78o(d)); and |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | the                  information contained in the Report fairly presents, in all material                  respects, the financial condition and results of operations of                  the                  Company. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Dated:                August 10, 2007 | /s/                Paul Van Ostenbridge            |
|---------------------------------------|----------------------------------------------------|
|                                  | Paul                Van Ostenbridge                |
|                                  | Chief                Executive Officer             |
|                                  |                                               |
|                                  |                                               |
| Dated:                August 10, 2007 | /s/                Julie Holland                   |
|                                  | Julie                Holland                       |
|                                  | Senior                Vice President and Treasurer |
EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE
SARBANES OXLEY ACT OF 2002

In connection with the Quarterly Report of Energy & Engine Technology
Corporation (the "Company") on Form 10-QSB for the period ending June 30,
2003 as filed with the Securities and Exchange Commission on the date hereof
(the "Report"), I, Roger N. Wurtele, CFO of the Company, do hereby certify
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Sections 13(a) or
    15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material
    respects, the financial condition and results of operations of the
    Company.

/s/ Roger N. Wurtele
Roger N. Wurtele
Chief Financial Officer

August 14, 2003


































                                   33
# Asian-American Pacific Islander Heritage Month Employee Spotlight: Charles Luhiau.

/ Published May 24, 2018
Richmond, Va., 
**Name:** Charles Luhiau

**Job Title:** Business Process Analyst

**Where do you physically work and what organization do you report to?**Tinker Air Force Base, DLA Aviation at Oklahoma City

**How long have you worked for DLA?** 20 years

**What does Asian-American and Pacific Islander Heritage Month mean to you?**It is a recognition and celebration of the culture and traditions by which I was raised. 

**Tell us something unique about your heritage or country of origin.**At this time the Big Island of Hawaii is currently being enlarged by the eruption of the Kilauea volcano. 

**What misconception about your heritage or country of origin would you like to correct?**Aloha does not just mean “Hello” and “Goodbye.” Aloha is a spirit of giving and charity, a spirit of goodness, unity, and community.

**What do you consider the most important cultural value for you and for those close to you?**The most important cultural value for us is Ohana Ho’okahi Na Ohana O Luhiau – Unity of the family of Luhiau. Ohana is family, be it the family that one is born into or the family of community that we choose to live our lives with.

**Tell us a little known fact that most people don’t know about you.**I taught myself Visual Basic for Applications (VBA), the programming language behind Microsoft Office.

**How important is it to you that Defense Logistics Agency Aviation recognize this month?**It is very important to me that DLA Aviation recognize this month that celebrates the spirit of Aloha and Ohana. The spirits and concepts of unity and family. We are all one team, we spend as much time with each other as we do our families, and we celebrate that sense of unity and kindness to one another.

**What do you want the DLA Aviation workforce to take away from celebrating this particular Month?**We are all in this together, working toward a common goal of serving the warfighter. We should feel Aloha towards each other as we are all Ohana.
II 

109TH CONGRESS 

1ST SESSION S. 1113 

To provide that no Federal funds may be expended for the payment or 

reimbursement of a drug that is prescribed for the treatment of sexual 

or erectile dysfunction. 

IN THE SENATE OF THE UNITED STATES 

MAY 24, 2005 

Mr. GRASSLEY (for himself, Mr. LOTT, Mr. SANTORUM, and Mr. ENSIGN) introduced the following bill; which was read twice and referred to the Committee on Finance 

A BILL 

To provide that no Federal funds may be expended for 

the payment or reimbursement of a drug that is prescribed for the treatment of sexual or erectile dysfunction. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Prescription Drug Cov5 erage Stewardship Act of 2005’’. 
2 

•S 1113 IS

1 SEC. 2. NO FEDERAL FUNDS FOR DRUGS PRESCRIBED FOR 

2 THE TREATMENT OF SEXUAL OR ERECTILE 

3 DYSFUNCTION. 

4 (a) RESTRICTION.— 

5 (1) IN GENERAL.—Notwithstanding any other 

6 provision of law, no Federal funds may be expended 

7 for the payment or reimbursement, including pay8 ment or reimbursement under the programs de9 scribed in paragraph (2), of a drug that is pre10 scribed for the treatment of sexual or erectile dys11 function, including for such a drug that is prescribed 

12 to an individual who has a conviction for sexual 

13 abuse, sexual assault, or any other sexual offense. 

14 (2) PROGRAMS DESCRIBED.—The programs de15 scribed in this paragraph are the medicaid program, 

16 the medicare program, the Federal employees health 

17 benefits program, the Defense Health Program, the 

18 program of medical care furnished by the Secretary 

19 of Veterans Affairs, health related programs admin20 istered by the Indian Health Service, health related 

21 programs funded under the Public Health Service 

22 Act, and any other Federal health program. 

23 (b) EFFECTIVE DATE.—Subsection (a) shall apply to 

24 drugs dispensed on or after the date of enactment of this 

25 Act. 

Æ
Court of Appeals

of the State of Georgia

ATLANTA,____________________

The Court of Appeals hereby passes the following order:

A17A0022. MICHAEL GREENWOOD v. THE STATE. 

Michael Greenwood was convicted of several offenses including theft by

taking in 2006. In March 2016, he filed a motion to modify his sentence. The trial

court denied his motion on April 13, 2016. Thereafter, Greenwood filed a motion in

arrest of judgment which the trial court considered to be a motion for reconsideration

and denied it on June 30, 2016. Greenwood filed a notice of appeal on July 29, 2016. 

Pretermitting whether the trial court’s order is directly appealable, we lack

jurisdiction because Greenwood’s notice of appeal is untimely. 

A notice of appeal must be filed within 30 days of the entry of the order sought

to be appealed. See OCGA § 5-6-38 (a). “The proper and timely filing of a notice

of appeal is an absolute requirement to confer jurisdiction upon an appellate court.”

Perlman v. Perlman, 318 Ga. App. 731, 739 (4) (734 SE2d 560) (2012) (citation and

punctuation omitted). The filing of a motion for reconsideration does not extend the

time for filing a notice of appeal, and the denial of such a motion is not directly

appealable. See State v. White, 282 Ga. 859, 860 (1) (655 SE2d 575) (2008); Bell v.

August 31, 2016
Cohran, 244 Ga. App. 510 (536 SE2d 187) (2000). Here, Greenwood filed his notice

of appeal 107 days after entry of the order he seeks to appeal. His appeal is therefore

untimely, and it is hereby DISMISSED for lack of jurisdiction.

Court of Appeals of the State of Georgia

Clerk’s Office, Atlanta,____________________

I certify that the above is a true extract from

the minutes of the Court of Appeals of Georgia.

Witness my signature and the seal of said court

hereto affixed the day and year last above written.

, Clerk.

08/31/2016
<partyblock><br><br><div align="center"><b><font size="+1">The People of the State of New York, Respondent,<br><br>against<br><br>Ismael Quinones, Defendant-Appellant.</font></b></div><br><br><p>Defendant appeals from a judgment of the Criminal Court of the City of New York, New York County (Lisa A. Sokoloff, J.), rendered October 5, 2015, convicting him, upon his plea of guilty, of criminal possession of a controlled substance in the seventh degree, and imposing sentence.</p><p>Per Curiam.</p><p>Judgment of conviction (Lisa A. Sokoloff, J.), rendered October 5, 2015, affirmed.</p><p>In view of the defendant's knowing waiver of his right to prosecution by information, the accusatory instrument is assessed under the standard applicable to a misdemeanor complaint (<a href="../2014/2014_04038.htm" target="_blank"><i>see People v Dumay</i>, 23 NY3d 518</a>, 522 [2014]). So viewed, the accusatory instrument was jurisdictionally valid because it described facts of an evidentiary nature establishing reasonable cause to believe that defendant was guilty of criminal possession of a controlled substance in the seventh degree (<i>see</i> Penal Law ยง 220.03). The deponent police officer's allegations that he identified the 16 pills recovered from defendant's pocket as Clonazepam, a controlled substance, based on his "professional training as a police officer in the identification of drugs, [his] prior experience as a police officer making drug arrests," and his "observation of the pills, which are characteristic of clonazepam," sufficed, in the context of a misdemeanor complaint, to show the basis for the conclusion that the substance at issue was a controlled substance (<i>see People v Dumas, </i>68 NY2d 729, 731 [1986]; <a href="../2015/2015_09188.htm" target="_blank"><i>see also People v Smalls</i>, 26 NY3d 1064</a> [2015]; <a href="../2009/2009_02446.htm" target="_blank"><i>People v Kalin</i>, 12 NY3d 225</a> [2009]; <a href="../2014/2014_51482.htm" target="_blank"><i>cf. People v Rosario</i>, 45 Misc 3d 127</a>[A], 2014 NY Slip Op 51482[U], [App Term, 1st Dept 2014]) . </p><br>THIS CONSTITUTES THE DECISION AND ORDER OF THE COURT.<br>I concur I concur<br>Decision Date: January 17, 2017<br><br><div align="center"><form method="LINK" action="../../slipidx/at_1_idxtable.shtml"><input type="submit" value="Return to Decision List"></form></div></partyblock>
**Exhibit 23.2**

 

**Consent ofIndependent Registered Public Accounting Firm**

 

TheBoard of DirectorsNeoPharm, Inc.:

 

We consent to the incorporation by reference in the registrationstatements (Nos. 333-03725, 333-66365, and 333-104586) on Form S-8 and(No. 333-109340) on Form S-3 of NeoPharm, Inc. of our reportdated April 28, 2005, with respect to management’s assessment of theeffectiveness of internal control over financial reporting as of December 31,2004 and the effectiveness of internal control over financial reporting as ofDecember 31, 2004, which report appears in the December 31, 2004 annualreport on Form 10-K/A of NeoPharm, Inc.

 
| /s/ KPMG  LLP |   |
|--------------------|--------|

 

Chicago,IllinoisApril 28, 2005

 

----
Final Listing of Questionnaire Files for Steam Electric Rulemaking Record

Plant ID 06178

Removed 

from Public 

(Non-CBI) 

Docket1

Copyright 

Flag2File Name3

Description

06178\06178_ Certification Statement.PDF Plant certification statement

x 06178\06178_Checklist_110410_version34.xls EPA Technical Review Checklist Workbook

06178\06178_Completeness Checklist.xls EPA Completeness Review Checklist

x 06178\06178_Part A.xls Plant submitted survey file

x 06178\06178_Part E.xls Plant submitted survey file

x 06178\06178_Part H.xls Plant submitted survey file

x 06178\Supporting Documents\06178_Cecil Lynch_Aerial Photo.pdf Plant submitted supplemental files to the survey

x 06178\Supporting Documents\06178_Cecil Lynch_Water Balance.pdf Plant submitted supplemental files to the survey

1

 Final reviewed survey responses are located in the Steam Electric Technical Questionnaire Database . 

2

 Copyright documents are available from the docket. 

3

 No hardcopy log is included for this plant as no hardcopy materials were received.
**Dairy Outlook (LDP-D)
A product of the Economic Research Service, U.S. Department of Agriculture**Description:**
**
# L_2023168EN.01000101.xml

| 3.7.2023 | EN | Official Journal of the European Union | L 168/1 |
| --- | --- | --- | --- |

3.7.2023

EN

Official Journal of the European Union

L 168/1

---

COMMISSION IMPLEMENTING REGULATION (EU) 2023/1340

of 26 June 2023

entering a name in the register of protected designations of origin and protected geographical indications (‘Varaždinsko bučino ulje’ (PGI))

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1151/2012 of the European Parliament and of the Council of 21 November 2012 on quality schemes for agricultural products and foodstuffs (1), and in particular Article 52(2) thereof,

Whereas:

| (1) | Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Croatia’s application to register the name ‘Varaždinsko bučino ulje’ was published in the Official Journal of the European Union (2). |
| --- | --- |

(1)

Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Croatia’s application to register the name ‘Varaždinsko bučino ulje’ was published in the Official Journal of the European Union (2).

| (2) | As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Varaždinsko bučino ulje’ should therefore be entered in the register, |
| --- | --- |

(2)

As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Varaždinsko bučino ulje’ should therefore be entered in the register,

HAS ADOPTED THIS REGULATION:

Article 1

The name ‘Varaždinsko bučino ulje’ (PGI) is hereby entered in the register.

The name specified in the first paragraph denotes a product in Class 1.5. – Oils and fats (butter, margarine, oil, etc.), as listed in Annex XI to Commission Implementing Regulation (EU) No 668/2014 (3).

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 26 June 2023.

For the Commission,

On behalf of the President,

Janusz WOJCIECHOWSKI

Member of the Commission

---

(1)  
  OJ L 343, 14.12.2012, p. 1.

1

(2)  
  OJ C 84, 7.3.2023, p 9.

2

(3)  Commission Implementing Regulation (EU) No 668/2014 of 13 June 2014 laying down rules for the application of Regulation (EU) No 1151/2012 of the European Parliament and of the Council on quality schemes for agricultural products and foodstuffs (OJ L 179, 19.6.2014, p. 36).

3

---
II 

109TH CONGRESS 

1ST SESSION S. 1660 

To extend the temporary suspension of duty on a certain ion exchange 

resin. 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 12, 2005 

Mr. SANTORUM introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL

To extend the temporary suspension of duty on a certain 

ion exchange resin.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ION EXCHANGE RESIN COMPRISING A 

4 COMPOLYMER OF STYRENE CROSSLINKED 

5 WITH ETHENYLBENZENE, AMINO-PHOS6 PHONIC ACID SODIUM FORM. 

7 (a) IN GENERAL.—Heading 9902.02.33 of the Har8 monized Tariff Schedule of the United States is amended 

9 by striking ‘‘12/31/2006’’ and inserting ‘‘12/31/2009’’. 
2

•S 1660 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to articles entered, or withdrawn 

3 from warehouse for consumption, on or after the 15th day 

4 after the date of the enactment of this Act.

Æ
Exhibit
99.1


Atlantic
BancGroup, Inc. announces third quarter 2008 results.





JACKSONVILLE
BEACH, FLORIDA, November 14, 2008





Atlantic
BancGroup, Inc., the parent company of Oceanside Bank, with four locations in
the Jacksonville Beaches and East Jacksonville, Florida, announced today its
third quarter 2008 results.





Oceanside
Bank remains well capitalized under current regulatory guidelines, despite
Atlantic BancGroup posting a net loss for the quarter ended September 30, 2008
of $839,000, a decline from consolidated net income of $201,000 in the same
period of 2007.  For the three months ended September 30, 2008, the
Company had a $0.68 loss per diluted share, as compared with $0.16 earnings per
diluted share for the same period of 2007.  “Our results for the third
quarter are a reflection of the economic downturn in our local market and
depressed real estate values.  Recent national and international
events that disrupted financial and credit markets will continue to affect our
cost of funds and net interest margins.  We continue to maintain a
close watch on asset quality as the real estate market struggles to find a
settling point.  Management believes that the Jacksonville Beaches
market will be resilient and the general economy will recover,” stated Chief
Executive Officer Barry W. Chandler.





The
results for the third quarter of 2008 included additional reserves to offset
loan charge-offs, recent real estate foreclosures, the effects from the slowdown
in real estate activity and sales on borrowers engaged in real estate
development and continued declines in the underlying collateral values of loans
secured by real estate.  During the third quarter, the bank added
$1,735,000 to our allowance for loan losses, as compared with $410,000 added in
the third quarter of 2007.  The cost to manage the loan portfolio and
carry foreclosed assets increased with direct expenses for foreclosed assets and
related net losses charged to operations totaling $66,000 for the quarter ended
September 30, 2008, as compared with none in the same period of 2007. Other
related costs such as collection, legal and audit expenses also increased in
2008 over 2007.





Mr.
Chandler continued, “consolidated total assets at September 30, 2008, were
$263.0 million, an increase of 1.9% over September 30,
2007.  Consolidated deposits and consolidated net loans grew 3.3% and
6.1% respectively, over the same period, with consolidated deposits at $208.5
million and consolidated net loans at $205.4 million at September 30,
2008.”





Atlantic
BancGroup, Inc. is a publicly traded holding company, trading on the NASDAQ
Capital Market, symbol ATBC.